SXTP Sixty Degrees Pharmaceuticals
Price Chart
Executive Summary
60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Phase 2 clinical trial (NCT06207370) evaluating tafenoquine for babesiosis. Enrollment is tracking ahead of schedule, with minimum enrollment for an interim analysis potentially achieved as early as July 2026. The press release is a clinical update with no new financial data or efficacy results.
Actionable Insight
The enrollment update is incrementally positive for trial progress but provides no efficacy data or commercial de-risking. Given SXTP's micro-cap status ($4M market cap) and negative historical return patterns on prior analyses, the stock may react modestly to the ahead-of-schedule milestone, but the binary risk of interim results later in 2026 dominates. Traders should wait for the interim analysis data (expected ~Q3 2026) before establishing a directional position.
Key Facts
- First patient of the 2026 tick season enrolled in randomized, double-blind, placebo-controlled trial (NCT06207370) for tafenoquine in babesiosis.
- Minimum enrollment of 24 patients for interim analysis expected as soon as early July 2026, approximately one month ahead of schedule.
- Interim analysis date to be announced approximately 50 days after enrollment completion.
- Tafenoquine is already FDA-approved for malaria prophylaxis as ARAKODA, but not approved for babesiosis.
- Company has a market cap of approximately $4M, and historical filing reports on SXTP have produced negative average returns at T+5 and T+20.
- Score calibration data shows low observed win probability (30-32%) for impact scores 6-8 in this segment, and historical reports on SXTP have a 0% win rate at T+20 (n=2).
Financial Impact
No financial figures disclosed; the filing is a clinical enrollment update with no revenue, guidance, or financing details.
Risk Factors
- Tafenoquine is not FDA-approved for babesiosis; trial failure or negative interim analysis would be highly dilutive to valuation.
- Company has a going-concern warning (substantial doubt about ability to continue) disclosed in prior 10-K, increasing financing risk before trial completion.
- Historical stock performance on prior analyses shows negative mean returns at T+20 (-14.16%), and the score calibration for this segment indicates low reliability in impact scores.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301055 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
18d ago
|
Press Release
| $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $1.36 (−9.33%) |
|
May 15, 2026
28d ago
|
Press Release
| $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $1.36 (+2.16%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $1.36 (−22.29%) |
|
Mar 18, 2026
12w ago
|
Press Release
| $2.12 $1.55 | ▼ −26.89% | ▼ −26.17% | $1.36 (−35.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access